- Conditions
- Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
- Interventions
- NTX-001 (PEG-Fusion)
- Combination Product
- Lead sponsor
- Neuraptive Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Los Angeles, California • San Francisco, California • Orlando, Florida + 20 more
Location Directory
Clinical trials in Orlando, Florida
This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
6861
Shown on this page
12
Current sort
Recently updated
Location scope
Orlando, FL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 661–672 of 6,861 matching trials in Orlando, FL.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Gastric Varices Bleeding, Cirrhosis
- Interventions
- EUS-guided Coil and Cyanoacrylate Glue Injection, Endoscopic Cyanoacrylate Glue Injection
- Procedure
- Lead sponsor
- Medanta, The Medicity, India
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Cardiometabolic Disease
- Interventions
- AMG 513, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Anaheim, California • Lake Forest, California • Oxnard, California + 9 more
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Tarlatamab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Plainville, Connecticut • Orlando, Florida + 9 more
- Conditions
- Crohn Disease, Colitis, Ulcerative
- Interventions
- TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 18
- States / cities
- San Diego, California • Kissimmee, Florida • Orlando, Florida + 15 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Palifosfamide-Tris, doxorubicin, Placebo
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
- Conditions
- Obesity, Overweight
- Interventions
- Maridebart cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 3,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 71
- States / cities
- Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more
- Conditions
- HIV Infections
- Interventions
- CAB LA, New formulation of CAB LA
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 19 more
- Conditions
- Renal Impairment
- Interventions
- Sulthiame
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Altamonte Springs, Florida • Miami Lakes, Florida
- Conditions
- Heart Failure
- Interventions
- CDR132L, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years to 84 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Covina, California + 24 more
- Conditions
- HIV-1 Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 537 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 29 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- 100mg SPN-812, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 48 Months to 69 Months
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 54
- States / cities
- Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more